• Home
  • News
  • Analysis
  •  
    Regions
    • Australasia
    • Southeast Asia
    • Greater China
    • North Asia
    • South Asia
    • North America
    • Europe
    • Central Asia
    • MENA
  •  
    Funds
    • LPs
    • Buyout
    • Growth
    • Venture
    • Renminbi
    • Secondary
    • Credit/Special Situations
    • Infrastructure
    • Real Estate
  •  
    Investments
    • Buyout
    • Growth
    • Early stage
    • PIPE
    • Credit
  •  
    Exits
    • IPO
    • Open market
    • Trade sale
    • Buyback
  •  
    Sectors
    • Consumer
    • Financials
    • Healthcare
    • Industrials
    • Infrastructure
    • Media
    • Technology
    • Real Estate
  • Events
  • Chinese edition
  • Data & Research
  • Weekly Digest
  • Newsletters
  • Sign in
  • Events
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)870 240 8859

      Email: customerservices@incisivemedia.com

      • Sign in
     
      • Saved articles
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • RSS
    • Twitter
    • LinkedIn
    • Newsletters
  • Free Trial
  • Subscribe
  • Weekly Digest
  • Chinese edition
  • Data & Research
    • Latest Data & Research
      2023-china-216x305
      Regional Reports

      The reports review the year's local private equity and venture capital activity and are filled with up-to-date data and intelligence on fundraising, investments, exits and M&A. The regional reports also feature information on key companies.

      Read more
      2016-pevc-cover
      Industry Review

      Asian Private Equity and Venture Capital Review provides an independent overview of the private equity, venture capital and M&A activities in the Asia region. It delivers insights on investments made, capital raised, sector specific figures and more.

      Read more
      AVCJ Database

      AVCJ Database is the ultimate link between Asian dealmakers and those who provide advisory, financial, legal and technological services to the private equity, venture capital and M&A industries. It is packed with facts and figures on more than 153,000 companies and almost 117,000 transactions.

      Read more
AVCJ
AVCJ
  • Home
  • News
  • Analysis
  • Regions
  • Funds
  • Investments
  • Exits
  • Sectors
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)870 240 8859

    Email: customerservices@incisivemedia.com

    • Sign in
 
    • Saved articles
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
AVCJ
  • Greater China

Addor raises $241m for second China healthcare fund

  • Tim Burroughs
  • 05 March 2021
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Save this article  
  • Send to  

Addor Capital – a Chinese VC firm backed by Jiangsu High-Tech Investment Group, also known as Govtor Capital – has raised RMB1.56 billion ($241 million) for its second renminbi-denominated healthcare fund.

Jiangsu Govtor Yida Health Achievement Innovation Venture Fund II spent just two months in the market, despite what Addor described as a "capital winter" for the industry. It claimed that local managers had raised RMB698.8 billion as of November 2020, down 21.98% year-on-year.

LPs in the new fund include government guidance vehicles, state-owned enterprises, high net worth individuals (HNWIs), and corporates. AVCJ Research's records indicate that Getein Biotech and Zking Property & Casualty Insurance, as well as Govtor and Addor itself, are among the investors.

"The so-called capital winter is not because there is less money in the market, but because investors have become smarter. In the past two years, the private equity investment industry has reshuffled at an accelerated pace, and capital is increasingly concentrated in leading institutions. Small and medium-sized groups can no longer raise money because the returns have not met expectations. Investors are voting with their feet," said Yunzhong Shi, founding partner of Addor, in a statement.

A total of $36.6 billion was committed to renminbi funds in 2020, down from $49.6 billion the previous year, according to AVCJ Research. Fundraising topped $90 billion in each of 2016 and 2017, but then plunged by more than half the following year as the government introduced restrictions on how financial institutions could participate in the asset class.

Addor raised RMB1 billion for its debut healthcare vehicle in 2015, primarily relying on contributions from HNWIs. As of January 2020, the fund had invested in 28 small to medium-sized enterprises (SMEs). Two companies – Contec Medical Systems and Sansure Biotech – have gone public and three have been exited via trade sales. Ten more companies are preparing for IPOs.

Fund II will make earlier-stage investments and focus more on technology. Yi Xue, who leads Addor's healthcare investment team, identified two key driving factors: greater investment in healthcare systems, with COVID-19 having exposed the full extent of the needs in this area; and the technological decoupling of China and the US, which will have a significant impact on industrial supply chains.

Addor will also pay closer attention to innovative drug development. Xue noted that Fund I was relatively light in this area because drug developers have long R&D cycles and large capital needs, and they are difficult to exit. However, capital market reforms permitting listings by pre-revenue biotech companies on Shanghai's Star Market have changed the industry landscape. At the same time, more domestic biotech talent is returning to China and founding start-ups.

As of January 2021, Addor had accumulated RMB113.7 billion in assets under management and invested in 957 companies, of which more than 100 are in the healthcare sector. It has seen 205 portfolio companies listed domestically or overseas. The firm manages several fund series that pursue venture, growth, M&A, sector-specific, region-specific, and foreign currency strategies.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Save this article  
  • Send to  
  • Topics
  • Greater China
  • Renminbi fund
  • Healthcare
  • Fundraising
  • GPs
  • China
  • Addor Capital

More on Greater China

Lower valuations, less leverage could drive China PE returns - HKMA Forum
Lower valuations, less leverage could drive China PE returns - HKMA Forum
  • Greater China
  • 09 November 2023
Ascendent bids $1.6b for China's Hollysys Automation
Ascendent bids $1.6b for China's Hollysys Automation
  • Greater China
  • 07 November 2023
Sinovation-developed LLM platform hits $1b valuation
Sinovation-developed LLM platform hits $1b valuation
  • Greater China
  • 06 November 2023
PE-backed Guoquan Food raises $52.5m in Hong Kong IPO
PE-backed Guoquan Food raises $52.5m in Hong Kong IPO
  • Greater China
  • 06 November 2023

Latest News

Asian GPs slow implementation of ESG policies - survey
Asian GPs slow implementation of ESG policies - survey

Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...

  • GPs
  • 10 November 2023
Singapore fintech start-up LXA gets $10m seed round
Singapore fintech start-up LXA gets $10m seed round

New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.

  • Southeast Asia
  • 10 November 2023
India's InCred announces $60m round, claims unicorn status
India's InCred announces $60m round, claims unicorn status

Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”

  • South Asia
  • 10 November 2023
Insight leads $50m round for Australia's Roller
Insight leads $50m round for Australia's Roller

Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.

  • Australasia
  • 10 November 2023
Back to Top
  • About AVCJ
  • Advertise
  • Contacts
  • About ION Analytics
  • Terms of use
  • Privacy policy
  • Group disclaimer
  • RSS
  • Twitter
  • LinkedIn
  • Newsletters

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013